CTLA4 and lymphoma: ADU-S100 was tested in combination with α-PD-1 spartalizumab (NCT03172936) [17] and anti-CTLA-4 antibody (α-CTLA-4) ipilimumab (NCT02675439) in patients with solid tumors or lymphomas, respectively.